TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02400307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: 75 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: 75 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: 75 mg tablet administered orally
Study: NCT03088137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa (Gonal-f)
Description: Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (Primapur)
Description: Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
Study: NCT03248440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-131 1.5% TDS
Description: SUN-131 1.5% TDS will be worn for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TDS
Description: No active substance; Placebo TDS will be worn each day for 14 days
Study: NCT01987375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: a single dose of the study drug following a single loading dose of unlabeled cetuximab
Study: NCT03255941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
Study: NCT01052662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 30mg/day Memantine orally everyday for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 15 mg/day Memantine orally everyday for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally everyday for 12 weeks
Study: NCT03070314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinaforce junior
Description: Echinacea Purpurea Extract Pill, sweetened and with orange flavour
Study: NCT01071889

Intervention type: DRUG
Group type: OTHER
Intervention: Flumazenil
Description: Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration

Intervention type: DRUG
Group type: OTHER
Intervention: Flumazenil
Description: Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo - only excipients with no API

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo - only excipients with no API
Study: NCT00372060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: sitagliptin phosphate (MK0431)
Description: Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: pioglitazone
Description: pioglitazone once daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone once daily for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Placebo once daily for 12 weeks
Study: NCT01148043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg capsule, 2 capsules QD for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: capsule, 2 capsules QD for 24 weeks
Study: NCT03198260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial manipulation
Description: Deep frictional massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial manipulation
Description: Deep frictional massage
Study: NCT02278575

Intervention type: DRUG
Group type: OTHER
Intervention: Atenativ
Description: intravenous transfusion
Study: NCT01680120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia
Description: Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12).
Study: NCT01579578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 40 mg, oral dose twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral dose twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV once weekly for 3 weeks followed by a week off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV once weekly for 3 weeks followed by a week off.
Study: NCT02920593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D prophylaxis
Study: NCT05058586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients
Description: Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients
Description: Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients
Description: Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
Study: NCT00918749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg
Description: 150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg
Description: 75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg
Description: 100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
Study: NCT02572206

Intervention type: RADIATION
Group type: OTHER
Intervention: PET/SPECT Scan
Description: PET scan will be performed on a mCT scanner.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Structural MRI will be obtained to permit co-registration of PET images.
Study: NCT01266148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
Study: NCT04389606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Formula (SF)
Description: New infant formula for term infants fed ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Formula (SF)
Description: New infant formula for term infants fed ad lib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Formula (CF)
Description: Commercially available infant formula for term infants fed ad lib
Study: NCT01337271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBT - NAVA
Description: An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
Study: NCT04389606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator Formula (CF)
Description: Commercially available infant formula for term infants fed ad lib
Study: NCT02575794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terameprocol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02547077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 2-octylcyanoacrylate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 2-octylcyanoacrylate
Study: NCT01642134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin+clopidogrel (Duoplavin)
Description: 100 mg aspirin ;75 mg clopidogrel 3º months
Study: NCT02547077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 5-0 Fast Absorbing Gut Sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 5-0 Fast Absorbing Gut Sutures
Study: NCT01445743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Tdap Vaccine
Description: Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
Study: NCT01642134

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: aspirin+clopidogrel (Duoplavin)
Description: 100 mg aspirin ;75 mg clopidogrel 3º months
Study: NCT00401817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg on day 1 of each of 6 cycles
Study: NCT01445743

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological/Vaccine: Tdap Vaccine
Description: Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
Study: NCT00401817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
Study: NCT02015663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
Study: NCT02306395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial local injury
Description: The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
Study: NCT03688542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Circle Deprescribing Module
Description: The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
Study: NCT03018106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene
Description: Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal conjugated estrogens
Description: Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
Study: NCT01113463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose of 160 mg/m\^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
Study: NCT00136916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study: NCT03660787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT03551353

Intervention type: OTHER
Intervention: Group before Video-assisted feedback
Description: Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
Study: NCT03510858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multilevel training intervention (intervention group)
Description: QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.

Intervention type: OTHER
Group type: OTHER
Intervention: Multilevel training intervention (control group with crossover)
Description: The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
Study: NCT03430973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bumper stickers
Description: Bumper stickers hypothesized to increase or decrease aggressive driving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-related cues
Description: Case of beer or water on passenger seat.
Study: NCT03551353

Intervention type: OTHER
Intervention: Group after Video-assisted feedback
Description: Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
Study: NCT00494845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: 8-week mindfulness program will be compared to an education control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: Health Education Class
Description: 8-week education program
Study: NCT02571400

Intervention type: OTHER
Intervention: Continued use of opioid analgesics >90 days post-surgery
Description: Exposure of interest: continued use of opioid analgesics \>90 days post-surgery